CLINICAL EFFICACY OF LOOP DIURETIC TORASEMIDE IN TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE. RESULTS OF KAZAKHSTAN MULTICENTER STUDY "POET"
https://doi.org/10.20996/1819-6446-2014-10-5-495-499
Abstract
Aim. To study the efficacy of loop diuretic torasemide compared with furosemide consisting of combination therapy in patients with chronic heart failure (CHF).
Material and methods. Inpatient and outpatient patients (n=136; 80 men and 56 women) with CHF class 2-3 (NYHA) living in different regions of Kazakhstan were included into the study.
Results. More pronounced decrease in edema syndrome, significant decrease in the rate of maladaptive myocardial remodeling, increase in systolic function by 8.2%, improving quality of life by 30.1% took place during combination therapy including loop diuretic torasemide compared with furosemide.
Conclusion. The loop diuretic torasemide consisting of combination therapy has a positive effect on myocardial remodeling and improves quality of life in patients with CHF class 2-3 (NYHA).
About the Authors
S. F. Berkinbaev
Institute of Cardiology and Internal Diseases
Kazakhstan
Aiteke-bi ul., 120, Almaty, Republic of Kazakhstan
Kazakhstan
Aiteke-bi ul., 120, Almaty, Republic of Kazakhstan
G. A. Dzhunusbekova
Institute of Cardiology and Internal Diseases
Kazakhstan
Aiteke-bi ul., 120, Almaty, Republic of Kazakhstan
Kazakhstan
Aiteke-bi ul., 120, Almaty, Republic of Kazakhstan
A. K. Isabekova
Institute of Cardiology and Internal Diseases
Kazakhstan
Aiteke-bi ul., 120, Almaty, Republic of Kazakhstan
Kazakhstan
Aiteke-bi ul., 120, Almaty, Republic of Kazakhstan
References
1. Juan CosínaJ., Díezb J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (4): 507-13.
2. National guidelines of SSHF, RCS and RSMST for diagnosis and treatment of chronic heart failure (fourth revision). Available at: http://upload.ossn.ru/medialibrary/574/574223742687ee0c61b85db0115308be/SSHF_Guidelines_rev.4.0.3.pdf. Accessed by 10/10/2014. Russian (Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). До-ступно на: http://upload.ossn.ru/medialibrary/574/574223742687ee0c61b85db0115308be/SSHF_Guidelines_rev.4.0.3.pdf. Проверено 10.10.2014).
3. Rector Th., Cohn J. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-mind, placebo-controlled trial of pimobendan. Am Heart J 1992; 124 (4): 1017-24.
4. Belenkov YN, Mareev VY On the classification of congestive heart failure at the turn of the century. Serdechnaya Nedostatochnost' 2000; 2 (3): 88-90. Russian (Беленков Ю.Н., Мареев В.Ю. К вопросу о клас-сификации хронической сердечной недостаточности на рубеже веков. Сердечная Недостаточ-ность 2000; 2(3): 88-90).
5. World Medical Association. World Medical Association Declaration of Helsinki. 52nd WMA General Assembly; 2004. Available at: http://www.wma.net/e/policy/pdf/17c.pdf. Accessed by 10.10.2014.
6. Kobalava ZD, Villevalde SV, Moiseyev VS. The value of different methods of evaluation of renal function to stratify cardiovascular risk. Kardiologiya 2007; 47 (12): 74-80. Russian (Кобалава Ж.Д., Вил-левальде С.В., Моисеев В.С. Значение различных методов оценки функционального состояния почек для стратификации сердечно-сосудистого риска. Кардиология 2007; 47(12): 74-80).
7. Lapich SN, Chubenko AV, Babich PNю Statistical methods in biomedical research using Excel. Kiev: Morion; 2001. Russian (Лапич С.Н., Чубенко А.В., Бабич П.Н. Статистические методы в медико-био-логических исследованиях с использованием Excel. Киев: Морион; 2001).
8. Friedel H., Buckley M. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991; 41(1): 81-103.
9. Kim E.J., Lee M.G. Pharmacokinetics and pharmacodynamics of intravenous torasemide in mutant Nagase analbuminetic rats. Biopharm. Drug Dispos 2003; 24(1): 27-35.
10. Hall WD. Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci 1999; 317: 176-82.
11. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Co Cardiol 1992; 20: 248-54.
12. Carrie BJ, Hilberman M, Schroeder JS, Myers BD. Albuminuria and the permselective properties of the glomerulus in cardiac failure. Kidney Int 1980; 17: 507–14.
13. Chow KM, Szeto CC, Wong TY et al. Risk factors for thiazide-induced hyponatraemia. QJM 2003; 96 (12): 911-7.
14. Kittleson M, Hurwitz S, Shah MR et al. Development of circulatory-renal limitations to angiotensinconverting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am CollCardiol 2003; 41 (11): 2029-35.
15. Mukhin NA, Fomin VV, Moiseev SV, Khamkhoev MS. Chronic heart failure and kidney disease: prospects for treatment. Consilium Medicum 2008; 9: 69-74. Russian (Мухин Н.А., Фомин В.В., Моисеев С.В., Хамхоева М.С. Хроническая сердечная недостаточность и поражение почек: перспекти-вы лечения. ConsiliumMedicum 2008; 9: 69-74).
16. Noe L.L., Vreeland M.G., Pezzella S.M., Trotter J.P. A pharmaeconomical assessment of torasemide and furosemide in the treatment of patients with congestive heart failure. ClinTher 1999; 21(5): 854-6.
17. Muller K, Gamba G, Jaquet F et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail 2003; 5 (6): 793–801.
18. Puschett J.B. Pharmacological classification and renal actions of diuretic. Cardiology 1994; 84 Suppl 2: 4-13.
19. Uchida T., Yamanaga K., Kido H. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84 (Suppl 3): 14-7.
20. Uchida T., Yamanaga K., Nishikawa M. et al. Antialdosteronic effects of torasemide. Eur J Pharm 1991; 205: 145-50.
Review
For citations:
Berkinbaev S.F., Dzhunusbekova G.A., Isabekova A.K. CLINICAL EFFICACY OF LOOP DIURETIC TORASEMIDE IN TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE. RESULTS OF KAZAKHSTAN MULTICENTER STUDY "POET". Rational Pharmacotherapy in Cardiology. 2014;10(5):495-499. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-5-495-499
Views:
966
Email this article 